INTRODUCTION
============

Low birth weight (LBW) is one of the most problematic conditions affecting human populations. It is a very common complication of pregnancy, affecting up to 19% of all births in the developing world and between 5 and 7% of births in developed countries ([@b41-0071185]). Either as a consequence of poor growth *in utero*, preterm birth or a genetic abnormality, some babies are born too small and are consequently more vulnerable to complications at the time of birth, with increased risk of mortality ([@b43-0071185]). Furthermore, it is increasingly recognised that, although these vulnerable babies can gain weight and seem to recover from their poor start in life, many will experience complications in later life, including alterations in behaviour (ADHD, depression) and metabolism (obesity, type 2 diabetes, heart disease) ([@b16-0071185]). Identifying the molecular origins of growth restriction is crucial in identifying the most appropriate management of LBW infants to ensure optimal short- and long-term health outcomes.

Genomic imprinting is an epigenetic phenomenon that drives the preferential expression of certain genes from one parental allele ([@b21-0071185]). In humans, a number of childhood growth disorders, including Beckwith-Wiedemann syndrome (BWS; MIM \#130650) and Silver-Russell syndrome (SRS; MIM \#180860), involve the aberrant expression of imprinted genes ([@b11-0071185]). These imprinting disorders are rare at 1 in 13,000 and 1 in 300,000 births, respectively. However, numerous imprinted genes play a key role in regulating fetal growth and placental development in a dosage-sensitive manner, with paternal silencing primarily of growth-restricting genes and maternal silencing of growth-promoting genes ([@b40-0071185]), which suggests that aberrant imprinting might underlie more common human growth disorders.

Pleckstrin homology-like domain family A member 2 (*PHLDA2*) was first highlighted as a potential fetal growth restriction gene in a 2006 study that reported elevated expression in the placenta of 9 out of the 38 fetal growth restriction (FGR) placentae ([@b31-0071185]). Subsequently, several studies have examined *PHLDA2* in relation to fetal growth and birth weight ([@b20-0071185]). Whereas some of these studies have supported a role for elevated *PHLDA2* in LBW ([@b1-0071185]; [@b17-0071185]; [@b29-0071185]), others did not find a clear correlation with birth weight ([@b26-0071185]; [@b28-0071185]).

We previously reported on a growth restriction phenotype in mice that was linked to the presence of three copies of a bacterial artificial chromosome (BAC) spanning the murine *Phlda2* locus and a second imprinted gene, solute carrier family 22, member 18 (*Slc22a18*) ([@b35-0071185]; [@b38-0071185]). Transgenic fetuses were 13% lighter than control littermates late in gestation, with significant placental stunting phenotype and a severe loss of placental glycogen. However, these studies did not establish a direct link between elevated *Phlda2* expression and fetal growth restriction, nor did they model the more subtle elevations in expression reported in human studies. Here, we sought to clarify the role of the *Phlda2* gene in regulating fetal growth by using transgenic mice carrying a single-copy transgene. We report that as little as twofold increased expression of *Phlda2* was sufficient to reduce birth weight by 10%. Importantly, growth restriction was asymmetric, with relative sparing of the brain, followed by rapid catch-up growth after birth, classic features of placental insufficiency.

RESULTS
=======

In our previous paper, gene expression analysis of a newly generated BAC transgenic line on mixed genetic background suggested the presence of at least two copies of the BAC transgene ([@b38-0071185]). However, when we bred this line fully into the 129S2/SvHsd (129) genetic background (\>eight generations) and re-examined gene expression, the data was more consistent with the presence of a single copy ([Fig. 1A](#f1-0071185){ref-type="fig"}). When we examined fetal weight in the context of twofold gene expression, growth restriction of *Phlda2*^+/+BACx1^ fetuses was apparent at embryonic day 18.5 (E18.5; 1184.4±8.7 mg versus 1073.8±18.5 mg, *P*=5.33×10^−6^) but not at E14.5 or E16.5 ([Fig. 1B](#f1-0071185){ref-type="fig"}), similar to the growth profile we reported in response to fourfold expression ([@b38-0071185]). Transgenic placentae were 10--20% lighter than non-transgenic placentae at each time point ([Fig. 1C](#f1-0071185){ref-type="fig"}), similar to the weight reduction we reported for a single-copy transgenic line spanning *Phlda2*, *Slc22a18* and *Cdkn1c* ([@b38-0071185]).

![**Characterisation of the single-copy line BACx1 on a 129 strain background.** (A) QPCR analysis of *Phlda2* and *Slc22a18* expression in E14.5 *Phlda2*^+/+BACx1(129)^ placentae. (B) Fetal wet weights on the 129 genetic background at E14.5, E16.5 and E18.5. *Phlda2*^+/+BACx1(129)^ (2×) fetuses (*n*=36) were significantly lighter at E18.5, weighing 90.7% of the weight of their non-transgenic counterparts (*P*=5.33×10^−6^). (C) Placental wet weights on the 129 genetic background. *Phlda2*^+/+BACx1(129)^ (2×) placentae were significantly lighter that non-transgenic placentae at each time point. Numerical data is given in [supplementary material Table S1](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.017079/-/DC1). NS, not significant (*P*\>0.05), \**P*\<0.05, \*\*\**P*\<0.005.](DMM017079F1){#f1-0071185}

###### TRANSLATIONAL IMPACT

**Clinical issue**

Low birth weight is one of the most intractable and yet clinically relevant complications affecting human pregnancies. Being born small increases the risk of complications at the time of birth and can lead to early mortality. In addition, although low-birth-weight babies often gain weight and seem to recover from their poor start in life, babies with accelerated postnatal weight gain after *in utero* growth restriction have a greatly increased risk of developing type 2 diabetes, obesity and cardiovascular disease in later life compared with normal-birth-weight babies. Although the causes of low birth weight are numerous and include both genetic and environmental factors, elevated placental expression of the imprinted gene *PHLDA2* has been reported in a number of studies on low birth weight. However, because correlation does not always equal causation, determination of the relevance of elevated *PHLDA2* expression using an animal model is of crucial importance.

**Results**

In this study, the authors generated a mouse model in which *Phlda2* expression was elevated twofold, a similar increase in expression to that reported in human studies. The authors observed late fetal growth restriction in the transgenic mice, with the pups being born with a low birth weight. Crucially, growth restriction was asymmetric, with relative sparing of the brain, followed by rapid catch-up growth after birth, which are classic features of placental insufficiency. Moreover, growth restriction showed strain-specific differences and the effects of *Phlda2* overexpression were only apparent in mouse strains in which the placenta was already working at maximum capacity.

**Implications and future directions**

These findings support a causal role for elevated *PHLDA2* in the aetiology of human low birth weight. Moreover, the observation of both asymmetrical growth restriction and rapid catch-up growth in this new mouse model of *Phlda2* overexpression suggests that human infants born with a low birth weight owing to this specific alteration might be at higher risk of later-life health complications than infants born with a low birth weight for other reasons. This possibility can be investigated by reexamining data from human cohorts and through further work on the animal model. Finally, these findings suggest that elevated *PHLDA2* expression might be most harmful in scenarios in which the placenta is working at maximum capacity, such as in pregnancies subject to prenatal adversity.

To formally test whether the line carried a single copy of the transgene, we crossed males carrying the BAC with females carrying a paternally inherited targeted allele of *Phlda2*, also bred for \>eight generations into the 129 genetic background. This cross generated four genotypes: *Phlda2*^+/+(129)^ (one active copy of *Phlda2* and *Slc22a18*), *Phlda2*^+/+BACx1(129)^ (two active copies *Phlda2* and *Slc22a18*), *Phlda2*^−/+(129)^ (maternal-knockout *Phlda2*, equivalent to loss of function) and *Phlda2*^−/+BACx1(129)^ (double transgenic; one active copy of *Phlda2* and two active copies of *Slc22a18*). At E14.5, *Phlda2* was expressed at wild-type levels in double-transgenic fetuses, whereas *Slc22a18* remained elevated, confirming that the line carried a single extra copy of *Phlda2* ([Fig. 2A](#f2-0071185){ref-type="fig"}). Importantly, these double-transgenic fetuses exposed to a single dose of *Phlda2* and a double dose of *Slc22a18* were not significantly different in weight to controls at E18.5 (1123.3±13.8 mg versus 1144.3±23.4 mg, *P*=0.415; [Fig. 2B](#f2-0071185){ref-type="fig"}), whereas fetuses carrying the single-copy BAC transgene, exposed to a double dose of both genes (*Phlda2*^+/+BACx1(129)^), weighed less than controls (1123.3±13.8 mg versus 1038.7±23.4 mg, *P*=0.00180; [Fig. 2B](#f2-0071185){ref-type="fig"}). This finding genetically assigned growth restriction to the twofold-elevated *Phlda2* expression. As observed with a different single-copy BAC transgene ([@b38-0071185]), normalising the dose of *Phlda2* also returned placental weights to normal ([Fig. 2C](#f2-0071185){ref-type="fig"}).

![**Isolating a causative role for elevated *Phlda2* in inducing late fetal growth restriction (129 strain background).** (A) QPCR analysis of *Phlda2* and *Slc22a18* expression in E14.5 *Phlda2*^+/+^*^(129)^* (wild type; non-transgenic) versus *Phlda2*^−/+BACx1(129)^ (1×) (double transgenic) from litters containing all four genotypes. *Phlda2* expression was normal in double-transgenic placenta. (B) E18.5 fetal wet weights for *Phlda2*^+/+^*^(129)^* (WT), *Phlda2*^+/+BACx1(129)^ (BACx1; 2×), *Phlda2*^−/+(129)^ (KO; 0×) and *Phlda2*^−/+BACx1(129)^ (KO & BACx1; 1×) from litters containing all four genotypes on the 129 genetic background. Fetal growth restriction was attenuated in double-transgenic fetuses. *Phlda2*^−/+(129)^ (0×) fetuses were similar in weight to controls. (C) E18.5 placental wet weights for the litters used to generate data in [Fig. 2B](#f2-0071185){ref-type="fig"}. Placental growth restriction was apparent only when *Phlda2* expression was elevated (*Phlda2*^+/+BACx1(129)^). *Phlda2*^−/+(129)^ (0×) placentae were 33% heavier than controls. Numerical data is given in [supplementary material Table S2](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.017079/-/DC1). NS, not significant (*P*\>0.05), \*\**P*\<0.01, \*\*\**P*\<0.005.](DMM017079F2){#f2-0071185}

Loss of function of *Phlda2* has previously been characterised on the C57BL/6 genetic background ([@b15-0071185]; [@b35-0071185]). We similarly observed substantial placental overgrowth on the 129 background. *Phlda2*^−/+(129)^ placentae weighed 33% more than control placentae at E18.5 (94.9±4.1 mg versus 71.5±0.9 mg; *P*=8.41×10^−8^; [Fig. 2C](#f2-0071185){ref-type="fig"}). As in the study of *Phlda2* loss of function on the BL6 background, *Phlda2*^−/+(129)^ fetuses, which lacked the maternal *Phlda2* allele, were not advantaged by the possession of a larger placenta and weighed the same as their non-transgenic counterparts at E18.5 (1116.1±19.1 mg versus 1123.3±13.8; *P*=0.753; [Fig. 2B](#f2-0071185){ref-type="fig"}). These data formally assigned the late fetal growth restriction phenotype to twofold-elevated expression of *Phlda2* and confirmed that loss of function of *Phlda2* does not induce fetal overgrowth.

Fetal growth restriction due to placental insufficiency is often asymmetric, with a relative reduction in fetal kidney, liver, pancreas and lung size but a sparing of the brain. When organ weights of the four genotypes were compared at E18.5, the brain weights of the *Phlda2*^+/+BACx1^ fetuses were 10% heavier relative to body weight as compared to the non-transgenic fetuses, suggestive of brain sparing ([Fig. 3A](#f3-0071185){ref-type="fig"}). The lungs and heart were proportionately growth restricted, whereas the liver and kidney, sites of embryonic *Phlda2* expression ([@b33-0071185]), were growth restricted as a proportion of body weight ([Fig. 3A](#f3-0071185){ref-type="fig"}). Brain sparing was similarly apparent in newborn mice carrying three copies of the transgene (*Phlda2*^+/+BACx3^) examined on the 129 genetic background ([Fig. 3B](#f3-0071185){ref-type="fig"}). Normalising the dose of *Phlda2* restored symmetry to the fetus ([Fig. 3A](#f3-0071185){ref-type="fig"}). These data genetically demonstrated that twofold elevated *Phlda2* restricts fetal growth asymmetrically. Moreover, loss of function of *Phlda2* had no significant consequence for these organ weights, excluding a reciprocal function for *Phlda2* in regulating organ weights.

![***Phlda2*-induced fetal growth restriction is asymmetric (129 strain background).** (A) Ratio of brain, lungs, heart, liver and kidney wet weights at E18.5 expressed as a proportion of body weight taken from samples described in [Fig. 2](#f2-0071185){ref-type="fig"}. Brain weight was heavier as a proportion of body weight, compared with controls, whereas liver and kidney, sites of embryonic *Phlda2* expression, were lighter. Normalising *Phlda2* expression restored organ weight to non-transgenic proportions. (B) Ratio of brain as a proportion of body weight in E18.5 fetuses carrying three copies of the BAC transgene, *Phlda2*^+/+BACx3(129)^ (4×). (C) Fetal and postnatal weight data for the line *Phlda2*^+/+BACx3(129)^ (4×). Transgenic fetuses were lighter at birth but rapidly gained weight such that there was no significant difference in weight to their non-transgenic counterparts by P7. Numerical data is given in [supplementary material Table S3](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.017079/-/DC1). NS, not significant (*P*\>0.05), \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.005.](DMM017079F3){#f3-0071185}

Catch-up growth is a key feature of extrinsically driven fetal growth restriction ([@b34-0071185]). When postnatal weights for line *Phlda2*^+/+BACx3^ were examined from birth (P0) until 4 weeks of age (P28), pups were born weighing 11% less than their non-transgenic counterparts (1.25±0.014 g versus 1.41±0.009 g; *P*=3.29×10^−17^). Within 7 days, there was no significant difference in the weights between transgenic and non-transgenic pups (*P*=0.147; [Fig. 3C](#f3-0071185){ref-type="fig"}).

Placental weight and fetal:placental (F:P) ratios are widely used as a parameter of placental functional capacity ([@b14-0071185]). The F:P ratio for mice of the 129 genetic background at E18.5 is relatively high, at 16.0±0.23, whereas that of C57BL/6 (BL6) mice is lower, at 12.3±0.18 ([@b39-0071185]). This suggests that BL6 placenta might have a greater reserve capacity than 129 placenta. To investigate whether *Phlda2* similarly restrained fetal growth in the context of a more favourable F:P ratio, we bred *Phlda2*^+/+BACx1^ and *Phlda2*^+/+BACx3^ (three copy line) mice onto the BL6 genetic background for \>eight generations. We observed no difference in fetal weight at E14.5, E16.5 or E18.5 ([Fig. 4A](#f4-0071185){ref-type="fig"}) despite transgenic placentae weighing 10--15% less than non-transgenic placentae at each time point ([Fig. 4B](#f4-0071185){ref-type="fig"}). When we examined F:P ratios, there was a significant difference from normal at every time point due to the reduction in weight of the placenta but not the fetus on the BL6 background ([Fig. 4C](#f4-0071185){ref-type="fig"}). F:P ratios were also significantly different from normal at E14.5 and E16.5 on the 129 background. At E18.5, there was no significant difference in F:P ratio because, at this later time point, both placental and fetal weights were reduced. This suggests that 129 placentae function at maximum capacity late in gestation and consequently cannot compensate for the reduction in capacity induced by elevated *Phlda2*, resulting in fetal growth restriction

![**Absence of fetal growth restriction on the BL6 genetic background.** (A) Fetal wet weights on the BL6 genetic background at E14.5, E16.5 and E18.5 for *Phlda2*^+/+BACx1(BL6)^ (2×), and at E18.5 for *Phlda2*^+/+BACx3(BL6)^ (4×). Fetuses were the same weight as their non-transgenic counterparts at each time point. (B) Placental wet weights on the BL6 genetic background at E14.5, E16.5 and E18.5 for *Phlda2*^+/+BACx1(BL6)^ (2×) and at E18.5 for *Phlda2*^+/+BACx3(BL6)^ (4×). Placentae were significantly lighter that non-transgenic placentae at each time point. (C) Fetal:placental (F:P) weight ratios. Ratios were significantly different compared with non-transgenic mice at each time point on the BL6 genetic background, but only at E14.5 and E16.5 on the 129 genetic background. Numerical data is given in [supplementary material Table S4](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.017079/-/DC1). NS, not significant (*P*\>0.05), \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.005.](DMM017079F4){#f4-0071185}

A reduced junctional zone and loss of placental glycogen have been linked to fetal growth restriction in several studies ([@b18-0071185]; [@b32-0071185]; [@b42-0071185]; [@b44-0071185]). Furthermore, placental glycogen has been suggested as an important source of easily utilisable energy to support late embryonic growth ([@b12-0071185]). In addition to the difference in F:P ratios, BL6 placentae have a disproportionately larger junctional zone and significantly greater stores of placental glycogen than 129 placentae ([@b39-0071185]). *In situ* hybridisation with trophoblast specific protein alpha (*Tpbpa*), a marker for the junctional zone ([@b27-0071185]), revealed a reduction of the junctional zone at E14.5 on both the 129 and the BL6 genetic backgrounds for line *Phlda2*^+/+BACx1^ ([Fig. 5A](#f5-0071185){ref-type="fig"}). To establish to what extent elevated *Phlda2* compromised glycogen accumulation on the two genetic backgrounds, a biochemical determination of glycogen was performed at E14.5, E16.5 and E18.5. Twofold expression of *Phlda2* induced a 50--60% decrease in total glycogen on the 129 background and 40--45% decrease on the BL6 background, relative to the respective non-transgenic counterparts, at each time point ([Fig. 5B,C](#f5-0071185){ref-type="fig"}). A similar reduction was apparent for the three-copy line at E18.5 on both backgrounds ([Fig. 5B,C](#f5-0071185){ref-type="fig"}). Thus, elevated *Phlda2* similarly limited the accumulation of glycogen on both genetic backgrounds. However, although the amplitude of the effect was similar, a comparison of the amount of glycogen stored, expressed either relative to the weight of the placenta (mg/g) or as a total amount (mg), highlighted a striking finding. Whereas glycogen stores were compromised on both genetic backgrounds by elevated *Phlda2*, the compromised BL6 placentae (*Phlda2*^+/+BACx1(BL6)^) still contained three times more glycogen than the genetically uncompromised 129 placentae (*Phlda2*^+/+(129)^) ([Fig. 5D--F](#f5-0071185){ref-type="fig"}).

![**Placental glycogen attenuates fetal growth restriction.** (A) *In situ* hybridisation of *Tpbpa* riboprobe to E14.5 sections from *Phlda2*^+/+(129)^ and *Phlda2*^+/+BACx1(129)^ (2×) placenta in comparison to the same genotypes on the BL6 genetic background. Scale bars: 200 μm. (B) Biochemical determination of glycogen at E14.5, E16.5 and E18.5 for *Phlda2*^+/+BACx1^ and at E18.5 for *Phlda2*^+/+BACx3^ (4×) on the 129 background expressed as a percentage of values in non-transgenic placenta. (C) Biochemical determination of glycogen at E14.5, E16.5 and E18.5 for *Phlda2*^+/+BACx1^ and at E18.5 for *Phlda2*^+/+BACx3^ on the BL6 background expressed as a percentage of values in control placenta. (D) 129 glycogen data from panel B expressed as mg/g of placenta. (E) BL6 glycogen data from panel C expressed as mg/g of placenta. (F) Comparison of total glycogen stored in E18.5 placenta on the 129 versus BL6 background. Compromised (*Phlda2* overexpression) BL6 placentae contain three times more glycogen than that found in the uncompromised (*Phlda2* wild-type expression) 129 placentae. Numerical data is given in [supplementary material Table S5](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.017079/-/DC1). \*\**P*\<0.01, \*\*\**P*\<0.005.](DMM017079F5){#f5-0071185}

Taken together, these data genetically define a role for elevated *Phlda2* in asymmetrically restricting late fetal growth but suggests that the growth-restricting properties of *Phlda2* manifest only in unfavourable circumstances in which the placenta is already functioning at its upper limit to support the growth demands of the rapidly growing fetus.

DISCUSSION
==========

Elevated expression of the imprinted gene *PHLDA2* has been reported in a number of studies on LBW and fetal growth restriction, but correlation does not always equal causation. Here, we have demonstrated, using a mouse model, that twofold elevated expression of *Phlda2* can restrain fetal growth late in gestation. Moreover, we have also shown that *Phlda2*-induced growth restriction is asymmetric, with a relative sparing of the brain alongside rapid postnatal catch-up growth. However, we did not observe a similar growth restriction on a different genetic background.

Mouse and human placentae differ substantially not only with respect to histologically classified lineages but also with respect to gene expression ([@b10-0071185]). Nonetheless, our data support a causal role for elevated *PHLDA2* in restricting fetal growth in human pregnancies. In the study by McMinn et al., \~25% of the placentae from growth-restricted babies showed increased expression of *PHLDA2* ([@b31-0071185]). Kumar et al. similarly reported elevated placental *PHLDA2* in relation to fetal growth restriction, and Diplas et al. reported a threefold increase in placental *PHLDA2* in very LBW babies ([@b23-0071185]; [@b13-0071185]). These data suggest that elevated *PHLDA2* might be a relatively common cause of LBW in human populations. Our findings in the mouse model that *Phlda2*-induced growth restriction was asymmetric, with relative sparing of the brain, followed by rapid catch-up growth, is consequently of significant importance. Human babies with these characteristics, particularly those with accelerated postnatal weight gain after *in utero* growth restriction, have a greatly enhanced risk of developing type 2 diabetes, obesity and cardiovascular disease \[[@b2-0071185]; [@b3-0071185]; [@b5-0071185]; [@b8-0071185]; [@b7-0071185]; [@b4-0071185]; [@b6-0071185]; [@b24-0071185]; [@b25-0071185]\]. These diseases are thought to reflect the programming of metabolic abnormalities *in utero* in response to limited nutrient supply acerbated by optimal or even excessive nutrition after birth. This suggests that babies with elevated placental *PHLDA2* might be at risk of these later-life health complications. Further work is required to follow up the later-life outcomes for babies with elevated *PHLDA2* and also our transgenic mice to identify the predictive value of *PHLDA2* as a biomarker.

Several human studies suggest that *PHLDA2* expression inversely correlates with birth weight even within normal pregnancies ([@b1-0071185]; [@b17-0071185]; [@b29-0071185]). Moreover, in a study of \>7000 samples over three cohorts, a *PHLDA2* promoter polymorphism was positively correlated with birth weight ([@b19-0071185]). An inverse correlation with LBW was not reproduced in two other studies ([@b26-0071185]; [@b28-0071185]), although these studies only looked at \~100 samples. In our previous investigation of *PHLDA2* expression in placentae from the Southampton Women's Study, we did not find a significant inverse association between placental *PHLDA2* and birth weight, but we did observe a slowdown in fetal femur growth late in gestation and a significant loss of bone density at age 4 years ([@b28-0071185]). In this current study, we found that the growth-restricting properties of *Phlda2* were apparent on the 129 and not the BL6 genetic background, despite similar proportional reductions in placental weight and glycogen stores. Both the human data and our mouse data can be reconciled if elevated *PHLDA2* only restricts fetal growth under certain circumstances, i.e. when the placenta is working at maximum capacity or when other factors, such as environmental exposures, limit placental capacity extrinsically. LBW is particularly prevalent in populations under severe socioeconomic stress; this could be due to a multitude of factors including poor diet, maternal stress and smoking. Human placental *PHLDA2* has been reported to be upregulated in response to maternal smoking; additionally, in an experimental rat model, both maternal calorie restriction and alcohol were found to result in significantly upregulated placental *Phlda2* ([@b9-0071185]; [@b37-0071185]). We did not identify a correlation between placental *PHLDA2* expression and maternal lifestyle in our relatively small study ([@b28-0071185]), but it might be pertinent to further explore the data on *PHLDA2* both with respect to asymmetry and catch-up growth while taking into account the degree of prenatal adversity experienced by the mother.

In summary, our work has identified a causative role for elevated *Phlda2* in inducing asymmetrical late fetal growth restriction. Importantly, our work also suggests that elevated *Phlda2* might be more harmful in scenarios where the placenta is working at maximum capacity, such as in pregnancies subject to prenatal adversity.

MATERIALS AND METHODS
=====================

Mouse strains and genotyping
----------------------------

Animal studies and breeding were approved by the Universities of Cardiff ethical committee and performed under a UK Home Office project licence (RMJ). All mice were housed together in one room throughout the study on a 12-hour light-dark cycle with lights coming on at 06.00 hour and a temperature range of 21±2°C with free access to water (tap water) and standard chow. The *Phlda2* transgenic lines *Phlda2*^+/+BACx1(129)^ (previously Tg^10--10^) and *Phlda2*^+/+BACx3(129)^ (previously Tg^10--15^) were bred for \>eight generations onto either the C57BL6 (Harlan, BL6) or the 129S2/SvHsd (Harlan, 129) strain backgrounds for phenotypic assessment. The *Phlda2* targeted allele was either maintained by paternal transmission on the BL6 background or crossed into the 129 background for \>eight generations.

Weighing studies and biochemical determination of placental glycogen concentration
----------------------------------------------------------------------------------

Fetal and placental wet weights were taken at the stated time points after a discernible plug. Genotyping data was obtained from yolk sac DNA as previously described ([@b15-0071185]; [@b22-0071185]). Glycogen was extracted from whole placenta, and resuspended in 1 ml of H~2~O and assayed according to the method of Lo et al. ([@b30-0071185]) at a dilution of 1 in 2 (129) or 1 in 10 (BL6).

Quantitative RNA analysis
-------------------------

Quantitative PCR of reverse-transcribed RNA (QRT-PCR) was performed and analysed as described ([@b36-0071185]; [@b38-0071185]).

Statistical analyses
--------------------

Statistical significance (probability values) was determined using the Student's *t*-test (two-tailed distribution and two-sample unequal variance) or the Mann-Whitney *U*-test.

Supplementary Material
======================

###### Supplementary Material

We thank Mary Cleaton and Charlotte Taylor for help with glycogen extraction, and Hugo Creeth for organ weighing.

**Competing interests**

The authors declare no competing financial interests.

**Author contributions**

S.J.T. performed the bulk of the experiments, analysed data and contributed to the writing of the manuscript. M.V.D.P. performed some of the animal work. R.M.J. conceived and designed the experiment, interpreted the data and wrote the paper.

**Funding**

S.J.T. was supported by BBSRC grant BB/J015156; M.V.D.P. was supported by a BBSRC doctoral training grant BB/F016557/1.

**Supplementary material**

Supplementary material available online at <http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.017079/-/DC1>

[^1]: Present address: MRC Clinical Sciences Centre, Imperial College London, Hammersmith Hospital Campus, London, W12 0NN, UK.
